Inpharma 1416 - 6 Dec 2003

■ The US FDA has approved an injectablesuspension of the gonadotropin releasing hormoneantagonist, abarelix [Plenaxis; PraecisPharmaceuticals]. Plenaxis, the first gonadotropinreleasing hormone antagonist available as a depotformulation, is indicated for the palliative treatment ofmen with advanced symptomatic prostate cancer, inwhom LHRH agonist therapy is not appropriate andwho refuse surgical castration, and have one or moreof the following: risk of neurological compromise dueto metastases; ureteral or bladder outlet obstructiondue to local encroachment or metastatic disease; orsevere bone pain from skeletal metastases persistingon narcotic analgesia.Praecis Pharmaceuticals Inc. PRAECIS PHARMACEUTICALSINCORPORATED Receives FDA Approval for Plenaxis. Media Release : 25Nov 2003. Available from: URL: http://www.praecis.com 809028616

1

Inpharma 6 Dec 2003 No. 14161173-8324/10/1416-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved